Cantargia - About the company
Cantargia is a public company based in Lund (Sweden), founded in 2010. It operates as a Developer of antibody-based therapy for the treatment of solid tumors and cancers. Cantargia has raised $1M in funding. The company has 3460 active competitors, including 1140 funded and 795 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.
Company Details
Developer of antibody-based therapy for the treatment of solid tumors and cancers. The company's lead product candidate CAN04, to block cancer cell signaling via the interleukin-1 system, which among other things can limit the inflammatory tumor uses for growth and defense strategy. CAN04 also stimulates the body's immune system to eliminate cancer cells.
Key Metrics
Founded Year
2010
Location
Lund, Sweden
Stage
Public
Total Funding
$1M in 3 rounds
Latest Funding Round
Investors
Ranked
491st among 3460 active competitors
Employee Count
31 as on Sep 30, 2026
Similar Companies
Exit Details
Public
Cantargia's IPO details
Cantargia got listed on Mar 17, 2015.
Click here to take a look at Cantargia's IPO in detail
Sign up to download Cantargia's company profile
Cantargia's funding and investors
Cantargia has raised a total funding of $1M over 3 rounds. Its first funding round was on Jul 05, 2013. Cantargia has 11 institutional investors.
Here is the list of recent funding rounds of Cantargia:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Dec 15, 2020 | 2368732 | Post IPO | 9958765 | 7857359 | 4042039 | 9659844 |
Feb 19, 2020 | 6155606 | Post IPO | 2299062 | 4561689 | 4767925 | |
Jul 05, 2013 | 7321532 | PE | 9086746 | 8045271 | 9139335 |
View details of Cantargia's funding rounds and investors
Cantargia's founders and board of directors
Founder? Claim ProfileCantargia's employee count trend
Cantargia has 31 employees as of Sep 26. Here is Cantargia's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Cantargia's Competitors and alternates
Top competitors of Cantargia include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Cantargia, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd | BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 77/100 | |
3rd | Kite Pharma 2009, Los Angeles (United States), Acquired | Developer of cancer immunotherapy products using genetic engineering | $97.7M | 76/100 | |
4th | Attovia 2023, Fremont (United States), Public | Developer of antibody-based therapeutics for immune-mediated diseases and oncology | $255M | 72/100 | |
5th | Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | 72/100 | |
6th | Elicio 2012, Cambridge (United States), Public | Developer of vaccines for treating cancer | $47.4M | 72/100 | |
7th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
8th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 71/100 | ||
9th | Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 71/100 | |
10th | Strand Therapeutics 2017, Cambridge (United States), Series B | Provider of platform to deliver mRNA therapeutics for multi functional treatments | $256M | 71/100 | |
491st | Developer of antibody-based therapy for the treatment of solid tumors and cancers | $1M | 52/100 |
Looking for more details on Cantargia's competitors? Click here to see the top ones
Cantargia's Investments and acquisitions
Cantargia has made no investments or acquisitions yet.
Reports related to Cantargia
Here is the latest report on Cantargia's sector:
News related to Cantargia
Media has covered Cantargia for a total of 12 events in the last 1 year, 6 of them have been about company updates and 1 about people movement.
•
Cantargia Announces IL-17 as Second Target for Bispecific CAN14 AntibodyAccess Newswire•Nov 09, 2026•Cantargia
•
Cantargia Presents Promising Early Results with Nadunolimab in MDS and AML Ahead of ASH 2026Access Newswire•Nov 04, 2026•Cantargia
•
•
•
•
Cantargia announces outcome in rights issue and resolves on a directed issue of warrants to Fenja CapitalStock Screener•Jun 24, 2026•Cantargia, Fenja Capital
•
Cantargia Publishes Interim Report for The First Quarter of 2026Access Newswire•May 19, 2026•Cantargia
•
Cantargia Announces AACR 2026 Presentation of Study Design and Supportive Pre-Clinical Data for Investigator-Initiated Nadunolimab Study in MSS CRCAccess Newswire•Apr 17, 2026•Cantargia
•
New Preclinical Data on Anti-Tumor Effects of Nadunolimab in Metastatic Colorectal Cancer Presented at the Keystone Cancer Immunotherapy ConferenceAccess Newswire•Mar 18, 2026•Cantargia
•
Are you a Founder ?
FAQs about Cantargia
Explore our recently published companies
- Pro City Supply - Tampa based, 2005 founded, Unfunded company
- Avesdex Unity Bank - Cambridge based, 2026 founded, Unfunded company
- Finova - Kumasi based, 2025 founded, Unfunded company
- Convello - Valsad based, 1998 founded, Unfunded company
- Akshat Green - Patna based, 2025 founded, Unfunded company
- Xunoia - Hyderabad based, 2025 founded, Unfunded company